Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...

Sanofi India Q3 Results Live : Sanofi India announced its Q3 results on November 7, 2024, revealing a significant decline in ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The acquisition of global rights to NJO from Sanofi is expected to contribute positively to EBITDA from 2025 onwards. Recordati SpA (RICFY) reported a robust free cash flow of 434.3 million euros, up ...

The Accumulus Platform Powers Sanofi’s Submissions to Multiple Regulators Around the World GlobeNewswire November 07, 2024 ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

On the way, it acquired Sanofi India's vaccine portfolio, which has helped it deliver double-digit domestic growth in the ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Janney Montgomery Scott LLC lessened its stake in Sanofi (NASDAQ:SNY – Free Report) by 0.3% in the third quarter, according ...